A molecule that inhibits coronavirus replication has excellent potential for development into a drug suitable for treating COVID-19.
COVID-19: Diet Plan and Lifestyle Modifications for the Unlock Phase
Healthy eating habits and adherence to physical activity are required during COVID-19 lockdown. WHO has prepared a set of general tips that you could follow during the lockdown to stay fit and healthy.
Healthy eating habits and adherence to physical activity are required during COVID-19 lockdown. WHO has prepared a set of general tips that you could follow during the lockdown to stay fit and healthy.
‘The new molecule proved to be a fast way to discover starting points for the design of pharmaceuticals.’
The new coronavirus has caused more than five million deaths. Many lives could have been saved with antiviral drugs, but no treatment of this type has been available to the healthcare system. During the pandemic, researchers around the world have tried to find a pharmaceutical, but the development of new medications often takes a long time. During the first months of the pandemic, researchers were able to determine the structure of the coronavirus and how it functions at the molecular level. One of the viral enzymes was identified as a promising target for a drug, which is a strategy that has been successful for other viral diseases, such as AIDS. The idea is to design a molecule with the ability to recognise and bind to the enzyme. This would block its activity and thereby prevent the virus from producing new virus particles, stopping the spread of the virus.
In 2020, researchers at Uppsala University, in collaboration with the Drug discovery and Development platform at Scilifelab, began to screen for inhibitors of the enzyme. They used computer models to identify molecules that can inhibit the enzyme’s activity.
Fluvoxamine: An OCD Drug can Prevent Covid-19 Patients from Hospitalization
Fluvoxamine has been proven among one such drug that could be used to treat COVID-19. Dozens of COVID patients showed no clinical deterioration in their symptoms when treated with a drug, fluvoxamine.
Fluvoxamine has been proven among one such drug that could be used to treat COVID-19. Dozens of COVID patients showed no clinical deterioration in their symptoms when treated with a drug, fluvoxamine.
“The most promising molecule shows the same ability to inhibit the replication of the new coronavirus as the active substance in Paxlovid, a combination drug recently approved for treating COVID-19. Our molecule works well on its own, and we have shown that the molecule is also effective against previously identified variants of the coronavirus,” says Jens Carlsson, associate professor and the article’s lead author.
Advertisement
Green Fungus or Aspergillosis and COVID-19 Infection
Green fungus or Aspergillosis is caused by a common mold, which exists both indoors and outdoors. Every day, people inhale Aspergillus spores, but it isn't harmful. However, it affects people who have a weak immune system. If the infection is left untreated, it can cause pneumonia.
Green fungus or Aspergillosis is caused by a common mold, which exists both indoors and outdoors. Every day, people inhale Aspergillus spores, but it isn't harmful. However, it affects people who have a weak immune system. If the infection is left untreated, it can cause pneumonia.
Mucormycosis (Black Fungal Disease): A Complication of COVID-19
Mucormycosis is spread by spores from the black fungus, Mycormycetes. It mainly affects people with a weak immune system and attacks the lungs and other organs of the body. It is also known as Black Fungal Disease.
Mucormycosis is spread by spores from the black fungus, Mycormycetes. It mainly affects people with a weak immune system and attacks the lungs and other organs of the body. It is also known as Black Fungal Disease.
